Drug Trial Radar · NCT07172919
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
14
Planned (sponsor's estimate)
Start
Jan 2, 2026
Primary completion
Jul 1, 2028
Study completion Jul 1, 2028
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Sep 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the safety and tolerability of the continuation of sotorasib with or without panitumumab and/or other anti-cancer therapies in participants continuing to derive benefit in Amgen-sponsored protocols.
Conditions
- Advanced Solid Tumors
Interventions
SotorasibDrug
Sotorasib will be administered orally as a tablet.
PanitumumabDrug
Panitumumab will be administered as an IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to approximately 18 months
Locations
13 sites in 9 countries. Site status is shown where the registry gives one.
Florida Cancer Specialists - Fort Myers
Fort Myers, Florida · Recruiting
University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Scientia Clinical Research Ltd
Randwick, New South Wales, Australia · Terminated
Centre Leon Berard
Lyon, France · Recruiting
Evangelische Lungenklinik
Berlin, Germany · Recruiting
Universitaetsklinikum Koln
Cologne, Germany · Recruiting
Henry Dunant Hospital Center
Athens, Greece · Recruiting
Theagenion Cancer Hospital
Thessaloniki, Greece · Recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, Italy · Recruiting
Aichi Cancer Center
Nagoya, Aichi-ken, Japan · Recruiting
National Hospital Organization Hokkaido Cancer Center
Sapporo, Hokkaido, Japan · Terminated
Universitaetsspital Basel
Basel, Switzerland · Recruiting
Taichung Veterans General Hospital
Taichung, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.